The fact that PIGF is upregulated and overexpressed in CRC cases that are resistant to antiangiogenic therapies216 suggests that PIGF is a crucial factor in overcoming anti-VEGF resistance, which might explain why aflibercept performed better than bevacizumab in xenograft models.217. Here, VEGFA is linked to colorectal carcinoma.